James Timothy Patrick Ryan - 12 May 2026 Form 4 Insider Report for BioNTech SE (BNTX)

Reporting relationship: Chief Legal Officer and Chief Business Officer
Issuer ticker: BNTX
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 May 2026, 16:07:47 UTC
Prior SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Humza Bokhari, Attorney-in-Fact

Key filing fact

James Timothy Patrick Ryan filed Form 4 for BioNTech SE (BNTX) on 13 May 2026.

Key facts

This page summarizes James Timothy Patrick Ryan's Form 4 filing for BioNTech SE (BNTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 May 2026, 16:07.

Change

Previous filing in this sequence was filed on 25 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002123964 Primary reporting owner

Ryan James Timothy Patrick

Relationship: Chief Legal Officer and Chief Business Officer
Address: C/O BIONTECH SE, AN DER GOLDGRUBE 12, MAINZ, GERMANY
Signature: /s/ Humza Bokhari, Attorney-in-Fact
Signature date: 13 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BNTX transaction Derivative

Option (right to buy)

Award

Transaction value
Shares: +12,586
Change %
Price: $0.000000^*
Shares after: 12,586
Date: 12 May 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 12,586
Exercise price
Footnotes: F1, F2, F3

BNTX transaction Derivative

Performance Share Unit

Award

Transaction value
Shares: +10,069
Change %
Price: $0.000000^*
Shares after: 10,069
Date: 12 May 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,069
Exercise price: $0.000000
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

Footnote F2

The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

Footnote F3

The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

Footnote F4

Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

SEC remarks

Chief Legal Officer and Chief Business Officer